Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
Rev. chil. endocrinol. diabetes ; 12(4): 208-215, 2019. tab, ilus
Article in Spanish | LILACS | ID: biblio-1088029

ABSTRACT

INTRODUCCIÓN: Si bien, los edulcorantes no nutritivos (ENN) estevia y D-tagatosa han sido reportados como seguros, han demostrado tener algunos efectos metabólicos tras su ingesta. OBJETIVO: Describir los efectos de la ingesta de estevia y D-tagatosa sobre el metabolismo de la glucosa y ácido úrico, y del apetito-saciedad, a partir de la evidencia disponible. MÉTODOS: Revisión descriptiva. Se realizó búsqueda en PubMed utilizando los siguientes términos y palabras clave: "stevia rebaudiana", "tagatose", "D-tagatose", "blood glucose", "insulin", "metabolic processes", "uric acid", "hyperuricemia", "appetite" o "satiety". El análisis de los estudios seleccionados fue discrecional. RESULTADOS: Existen estudios que demuestran efectos beneficiosos tras el consumo de estevia o D-tagatosa sobre el control glicémico, apetito y saciedad tanto en sujetos sanos como con alteraciones en el metabolismo de la glucosa. Por otra parte, un número importante de estudios que evalúan la ingesta de estevia reportan efectos nulos sobre dichos parámetros. En relación al ácido úrico, solo un estudio en sujetos con enfermedad renal crónica reporta aumento en la concentración de ácido úrico plasmático tras la ingesta de 500 mg/día de estevia. Pocos estudios han evaluado el efecto de la ingesta de D-tagatosa sobre uricemia, en sujetos sanos y diabéticos, reportando un aumento transitorio y significativo en los niveles de ácido úrico sérico, sin embargo, no se ha logrado demostrar un efecto hiperuricémico asociado. Es importante destacar que la metodología de los estudios revisados es heterogénea, especialmente en relación al tamaño muestral, tiempo, dosis y vía de adminitración del edulcorante. CONCLUSIÓN: La ingesta de estevia y D-tagatosa ha demostrado efectos beneficiosos sobre el metabolismo de la glucosa, el apetito y la saciedad. El efecto del consumo de D-tagatosa sobre ácido úrico sérico requiere mayor evidencia para demostrar su significancia clínica.


INTRODUCTION: No-nutritive sweeteners stevia and D-tagatose have been reported as safe according to their acceptable daily intake, however, they have been shown to have metabolic effects after their ingestion. OBJECTIVE: To describe the effects of stevia and D-tagatose intake on parameters associated to glucose, uric acid metabolism and on appetite-satiety, considering the available evidence. METHODS: Descriptive review. PubMed search was carried out to identify the totality of the published articles. The following terms and key words were used: "stevia rebaudiana", "tagatose", "D-tagatose", "blood glucose", "insulin", "metabolic processes", "uric acid", "hyperuricemia", "appetite" o "satiety". The analysis of the selected studies was discretionary. RESULTS: studies have shown beneficial effects of stevia and D-tagatose consumption on glycemic control, appetite and satiety in healthy subjects as well as subjects with impairment glucose metabolism. On the other hand, a significant number of studies evaluating estevia intake report null effects on these parameters. In relation to uric acid, only one study in subjects with chronic kidney disease reported an increase in plasmatic uric acid concentration after the intake of 500 mg/day of stevia. Several studies have evaluated the effect of D-tagatose intake on plasmatic uric acid, in healthy and diabetic subjects, reporting a transient and significant increase in serum uric acid levels, however, has not been able to demonstrate an associated hyperuricemic effect. It is important to highlight that the methodology of the studies reviewed is heterogeneous, especially in relation to sample size, dose administered, time and route of exposure to the sweetener. CONCLUSION: Stevia and D-tagatose intake has shown beneficial effects on glucose metabolism, appetite and satiety. The effects of the consumption of both sweeteners on uric acid require further study to demonstrate their clinic significance.


Subject(s)
Humans , Sweetening Agents/pharmacology , Uric Acid/metabolism , Blood Glucose/drug effects , Appetite/drug effects , Satiation/drug effects , Stevia/metabolism , Glucose/metabolism , Hexoses/pharmacology , Insulin/metabolism
2.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 40(2): 216-219, Apr.-June 2018. tab, graf
Article in English | LILACS | ID: biblio-959214

ABSTRACT

Objective: To evaluate the serum leptin levels in cannabis smokers. Methods: This was a cross-sectional population-based study of participants between the ages of 18 and 35 years. The data were collected through a self-administered questionnaire covering sociodemographic data and the use of psychoactive substances. Leptin levels were measured using a commercial ELISA kit. Results: Of the 911 participants, 6.7% were identified as cannabis smokers and had significantly lower leptin levels (p = 0.008). When stratified by gender, there was a significant decrease in leptin levels among male smokers (p = 0.039). Conclusion: Cannabis smoking was linked to leptin levels in men, suggesting that the response to biological signals may be different between men and women.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Young Adult , Marijuana Smoking/blood , Leptin/blood , Appetite/drug effects , Socioeconomic Factors , Brazil , Marijuana Smoking/physiopathology , Sex Factors , Cross-Sectional Studies , Surveys and Questionnaires
3.
Clinics ; 73: e411, 2018. tab
Article in English | LILACS | ID: biblio-974928

ABSTRACT

OBJECTIVE: To correlate the perceptions related to dietary intake with the domains and subscales of health-related quality of life (HRQL) in women with breast neoplasms receiving chemotherapy. METHODS: In this prospective study, 55 women with breast cancer were followed up during chemotherapy at three different times (T0, T1, T2). Before chemotherapy, perceptions related to food consumption were evaluated. HRQL was analyzed with the EORTC QLQ-C30 and Br23 instruments 21 days after each investigated cycle. The differences (T2-T0) in the subscales and HRQL domains were correlated with the differences (T2-T0) in the appetite scores. Spearman's correlation was used to verify a possible correlation between differences in functional and overall HRQL domains (T2-T0) and differences in appetite scores for certain foods and between the differences in some subscales of EORTC QLQ-C30 and Br23 (T2-T0) and differences in appetite scores for certain food groups (T2-T0). RESULTS: Correlations between pain and appetite for bitter taste and between an increased appetite for juices and pain intensification or fatigue were identified, and pain was correlated with an appetite for starchy foods. An appetite for vegetables, legumes and meat/eggs was correlated with physical function. The only significant correlation with social functions occurred between the appetite for sweet foods and these functions. We found a correlation between overall health, emotional function, social function and physical function and the appetite for juices. CONCLUSION: Chemotherapy alters the individual's relationship with food and, consequently, the individual's HRQL.


Subject(s)
Humans , Female , Adult , Middle Aged , Aged , Quality of Life/psychology , Breast Neoplasms/drug therapy , Carcinoma, Lobular/drug therapy , Carcinoma, Ductal, Breast/drug therapy , Food Preferences/drug effects , Antineoplastic Agents/adverse effects , Perception/drug effects , Appetite/drug effects , Reference Values , Time Factors , Breast Neoplasms/psychology , Prospective Studies , Analysis of Variance , Carcinoma, Lobular/psychology , Carcinoma, Ductal, Breast/psychology , Statistics, Nonparametric , Food Preferences/psychology
4.
Papua New Guinea medical journal ; : 23-34, 2011.
Article in English | WPRIM | ID: wpr-631381

ABSTRACT

The relationship between HIV (human immunodeficiency virus), food security and nutrition has become increasingly important to practitioners, policy makers and people living with HIV. In this paper we describe for the first time the connection between HIV and antiretroviral therapies, the extent of nutritional counselling for HIV-positive people and food security in Papua New Guinea (PNG). A total of 374 HIV-positive people who were over the age of 16 and who had been on antiretroviral therapy (ART) for more than two weeks were recruited from six provinces, using a non-probability, convenience sampling methodology. A subsample of 36 participants also completed an in-depth qualitative interview. Participants received nutritional advice when beginning ART which focused on three main domains, of which the first two were the most frequently mentioned: what foods to avoid; what foods to eat; and how frequently to eat. 72% of the sample reported that they had experienced an increase in their appetite. Of those who reported that their appetite had increased on ART 33% reported that they did not have enough food to satisfy hunger. People who lived in the capital city, Port Moresby, within the Southern Region of PNG, had significantly more difficulty with food security than those who lived in other regions of the country. Not having enough food was the third most commonly recorded reason for non-adherence to ART. Responses to the HIV epidemic in Papua New Guinea must also begin to address the phenomenon of food insecurity for people with HIV, in particular those who are receiving antiretroviral therapies and who live in the urban areas.


Subject(s)
Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Anti-Retroviral Agents/therapeutic use , Appetite/drug effects , Counseling , Food Supply , HIV Infections/drug therapy , Medication Adherence , Papua New Guinea , Qualitative Research , Urban Population
5.
Arq. bras. endocrinol. metab ; 54(1): 45-51, fev. 2010. tab, ilus
Article in English | LILACS | ID: lil-544031

ABSTRACT

OBJECTIVE: The purpose of this study was to compare the effects of consumption of different protein sources on food intake and energy expenditure in normal weight subjects. SUBJECTS AND METHODS: Breakfast preparations (casein, soy protein, whey protein or control) were ingested during seven consecutive days. Appetite, food intake, and energy expenditure were assessed. RESULTS: Casein consumption led to a lower energy intake than whey protein. There was lower energy intake on day 7 than on day 1 of the casein session. Soy protein preparations resulted in higher diet induced thermogenesis (DIT) than in control preparations. The respiratory quotient (RQ) obtained in the whey protein session was lower than the control and soy protein sessions. CONCLUSION: These results suggest that the consumption of different protein types leads to distinct effects on satiety (casein), DIT (soy protein), and/or RQ (whey protein).


OBJETIVO: O objetivo deste estudo foi comparar os efeitos do consumo de diferentes fontes proteicas na ingestão alimentar e gasto energético em indivíduos eutróficos. SUJEITOS E MÉTODOS: Preparações (caseína, proteína da soja, proteína do soro de leite ou controle) foram ingeridas no desjejum, durante sete dias consecutivos. RESULTADOS: A caseína resultou em menor ingestão calórica do que o soro de leite. Houve uma menor ingestão calórica no último dia da sessão da caseína em relação ao primeiro dia. Preparações contendo proteína da soja resultaram em maior termogênese induzida pela dieta (TID) em comparação às preparações controle. O cociente respiratório (CR) obtido na sessão do soro de leite foi menor que na sessão controle e da proteína da soja. CONCLUSÃO: Esses resultados sugerem que o consumo de diferentes tipos de proteínas resulta em efeitos distintos na saciedade (caseína), TID (proteína da soja) e/ou CR (proteína do soro).


Subject(s)
Female , Humans , Male , Young Adult , Appetite/drug effects , Dietary Proteins/pharmacology , Eating/drug effects , Energy Intake/drug effects , Energy Metabolism/drug effects , Analysis of Variance , Caseins/pharmacology , Dietary Proteins/classification , Dietary Proteins/standards , Milk Proteins/pharmacology , Obesity/prevention & control , Oxygen Consumption/drug effects , Statistics, Nonparametric , Satiation/drug effects , Soybean Proteins/pharmacology , Thermogenesis/drug effects , Young Adult
6.
An. acad. bras. ciênc ; 79(2): 261-283, June 2007. ilus
Article in English | LILACS | ID: lil-454597

ABSTRACT

The present article reviews the role of the serotoninergic system in the regulation of the sodium appetite. Data from the peripheral and icv administration of serotoninergic (5-HTergic) agents showed the participation of 5-HT2/3 receptors in the modulation of sodium appetite. These observations were extended with the studies carried out after brain serotonin depletion, lesions of DRN and during blockade of 5-HT2A/2C receptors in lateral parabrachial nucleus (LPBN). Brain serotonin depletion and lesions of DRN increased the sodium appetite response, in basal conditions, after sodium depletion and hypovolemia or after beta-adrenergic stimulation as well. These observations raised the hypothesis that the suppression of ascending pathways from the DRN, possibly, 5-HTergic fibers, modifies the angiotensinergic or sodium sensing mechanisms of the subfornical organ involved in the control of the sodium appetite. 5-HTergic blockade in LPBN induced to similar results, particularly those regarded to the natriorexigenic response evoked by volume depletion or increase of the hypertonic saline ingestion induced by brain angiotensinergic stimulation. In conclusion, many evidences lead to acceptation of an integrated participation resulting of an interaction, between DRN and LPBN, for the sodium appetite control.


Este artigo revisa o papel do sistema serotoninérgico no controle do apetite ao sódio. Dados derivados da administração periférica e icv de agentes serotoninérgicos demonstraram a participação de receptores 5-HT2/3 na modulação do apetite ao sódio. Estas observações foram estendidas com os estudos realizados após a depleção cerebral de serotonina, lesões do NDR e durante o bloqueio 5-HT2A/2C no núcleo parabraquial lateral (NPBL). A depleção cerebral de serotonina e as lesões do NDR aumentaram o apetite ao sódio, em condições basais, após depleção de sódio, durante a hipovolemia ou após a estimulação beta-adrenérgica. Estas evidências suscitaram a hipótese de que a supressão de vias ascendentes do NDR, possivelmente 5-HT, alteram os mecanismos angiotensinérgicos e a atividade dos sensores de sódio do órgão subfornicial envolvidos no controle do apetite ao sódio. O bloqueio serotoninérgico no NPBL induziu a resultados similares, particularmente aqueles relacionados com a resposta natriorexigênica provocada pela depleção de volume ou o aumento da ingestão de salina hipertônica induzida pela estimulação angiotensinérgica cerebral. Em resumo, as evidências convergem para a admissão de uma participação integrada resultante da interação recíproca entre NDR e NPBL objetivando controlar o apetite ao sódio.


Subject(s)
Animals , Rats , Appetite/physiology , Pons/metabolism , /drug effects , Sodium , Serotonin Antagonists/pharmacology , Sodium Chloride, Dietary/administration & dosage , Appetite/drug effects , Pons/drug effects , /metabolism
7.
Article in English | IMSEAR | ID: sea-94477

ABSTRACT

The endocannabinoid system (EC) plays a significant role in appetite drive and associated behaviours. Therefore attenuation of the activity of the EC system would have therapeutic benefit in treating disorders that might have a component of excess appetite drive or over-activity of the endocannabinoid system, such as obesity, ethanol and other drug abuse, and a variety of central nervous system and other disorders. Antagonists of cannabinoid receptors have been designed through rational drug discovery essential to exploit these novel targets for potential in obesity, metabolism, addiction, pain and neurologic disorders. Rimonabant is the only compound in this group which along this pathway is now approved as a selective CB (1) (cannabinoid receptor subtype 1) antagonist, or inverse agonist, in the European Union and India and under regulatory review in the United States for the treatment of obesity and associated cardiometabolic risk.


Subject(s)
Appetite/drug effects , Appetite Stimulants/metabolism , Arachidonic Acids/metabolism , Calcium Channel Blockers/metabolism , Cardiovascular Diseases/metabolism , Endocannabinoids/metabolism , Humans , India , Lipid Metabolism , Obesity/drug therapy , Polyunsaturated Alkamides/metabolism , Receptors, Cannabinoid/antagonists & inhibitors , Risk Factors
8.
Braz. j. med. biol. res ; 38(11): 1669-1675, Nov. 2005. ilus
Article in English | LILACS | ID: lil-414720

ABSTRACT

We determined if the dorsal raphe nucleus (DRN) exerts tonic control of basal and stimulated sodium and water intake. Male Wistar rats weighing 300-350 g were microinjected with phosphate buffer (PB-DRN, N = 11) or 1 æg/0.2 æl, in a single dose, ibotenic acid (IBO-DRN, N = 9 to 10) through a guide cannula into the DRN and were observed for 21 days in order to measure basal sodium appetite and water intake and in the following situations: furosemide-induced sodium depletion (20 mg/kg, sc, 24 h before the experiment) and a low dose of dietary captopril (1 mg/g chow). From the 6th day after ibotenic acid injection IBO-DRN rats showed an increase in sodium appetite (12.0 ± 2.3 to 22.3 ± 4.6 ml 0.3 M NaCl intake) whereas PB-DRN did not exceed 2 ml (P < 0.001). Water intake was comparable in both groups. In addition to a higher dipsogenic response, sodium-depleted IBO-DRN animals displayed an increase of 0.3 M NaCl intake compared to PB-DRN (37.4 ± 3.8 vs 21.6 ± 3.9 ml 300 min after fluid offer, P < 0.001). Captopril added to chow caused an increase of 0.3 M NaCl intake during the first 2 days (IBO-DRN, 33.8 ± 4.3 and 32.5 ± 3.4 ml on day 1 and day 2, respectively, vs 20.2 ± 2.8 ml on day 0, P < 0.001). These data support the view that DRN, probably via ascending serotonergic system, tonically modulates sodium appetite under basal and sodium depletion conditions and/or after an increase in peripheral or brain angiotensin II.


Subject(s)
Animals , Male , Rats , Ibotenic Acid/toxicity , Excitatory Amino Acid Agonists/toxicity , Appetite/drug effects , Drinking/drug effects , Raphe Nuclei/drug effects , Sodium, Dietary , Appetite/physiology , Buffers , Captopril/pharmacology , Furosemide/pharmacology , Drinking/physiology , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Sodium Potassium Chloride Symporter Inhibitors/pharmacology , Phosphates , Rats, Wistar , Time Factors
9.
Braz. j. med. biol. res ; 34(3): 407-411, Mar. 2001. ilus
Article in English | LILACS | ID: lil-281623

ABSTRACT

Rats rendered hypothyroid by treatment with methimazole develop an exaggerated sodium appetite. We investigated here the capacity of hypothyroid rats (N = 12 for each group) to respond to a low dose of captopril added to the ration, a paradigm which induces an increase in angiotensin II synthesis in cerebral areas that regulate sodium appetite by increasing the availability of circulating angiotensin I. In addition, we determined the influence of aldosterone in hypothyroid rats during the expression of spontaneous sodium appetite and after captopril treatment. Captopril significantly increased (P<0.05) the daily intake of 1.8 percent NaCl (in ml/100 g body weight) in hypothyroid rats after 36 days of methimazole administration (day 36: 9.2 + or - 0.7 vs day 32: 2.8 + or - 0.6 ml, on the 4th day after captopril treatment). After the discontinuation of captopril treatment, daily 1.8 percent NaCl intake reached values ranging from 10.0 + or - 0.9 to 13.9 ± 1.0 ml, 48 to 60 days after treatment with methimazole. Aldosterone treatment significantly reduced (P<0.05) saline intake before (7.3 + or - 1.6 vs day 0, 14.4 + or - 1.3 ml) and after captopril treatment. Our results demonstrate that, although hypothyroid rats develop a deficiency in the production of all components of the renin-angiotensin-aldosterone system, their capacity to synthesize angiotensin II at the cerebral level is preserved. The partial reversal of daily 1.8 percent NaCl intake during aldosterone treatment suggests that sodium retention reduces both spontaneous and captopril-induced salt appetite


Subject(s)
Animals , Rats , Aldosterone/therapeutic use , Appetite/drug effects , Captopril/administration & dosage , Hypothyroidism/drug therapy , Peptidyl-Dipeptidase A/administration & dosage , Sodium, Dietary , Administration, Oral , Angiotensin II/metabolism , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Captopril/therapeutic use , Rats, Wistar , Sodium/metabolism
10.
Rev. chil. nutr ; 27(Supl. 1): 188-93, ago. 2000. tab
Article in Spanish | LILACS | ID: lil-290247

ABSTRACT

Se revisa la farmacoterapia como coadyuvante del tratamiento de obesidad, tanto en la reducción de peso como en la mantención de peso reducido. Se presentan los diferentes fármacos clasificados de acuerdo a su mecanismo de acción en anorexígenos y/o sacietógenos, termogénicos y drogas que provocan malabsorción de macronutrientes. Se entrega información sobre eficacia en el largo plazo, destacándose que entre los medicamentos actualmente en uso, solo la sibutramina y el orlistat han podido demostrar un promedio de reducción del 10 por ciento del peso inicial. En un segundo plano están la fenilpropanolamina, efedrina/cafeína y fluoxetina que, si bien no están aprobados para el tratamiento de la obesidad, en estudios controlados presentan resultados que justifican su indicación en algunos pacientes obesos. Se revisan productos comercializados para el tratamiento de la obesidad sin evidencia científica de su utilidad (picolinato de cromo, ácido hidroxicítrico, l-carnitina, chitosan) y se mencionan las drogas no recomendables por el riesgo de efectos adversos, especialmente cardiovasculares y psiquiátricos o por el potencial adictivo tales como la anfetamina, dietilpropion y fenproporex, hormonas tiroideas, fármacos diuréticos y laxantes. Finalmente, a la luz del descubrimiento de los mecanismos biológicos y moleculares involucrados en la patogénesis de la obesidad, se plantea la aparición futura de nuevos agentes farmacológicos que estimulen el gasto energético y lipídico (estimulantes B3-adrenérgicos), o que modulen el apetito y la saciedad, como los análogos de leptina y CCK, e inhibidores del neuropéptido


Subject(s)
Humans , Appetite Depressants/pharmacokinetics , Obesity/drug therapy , Intestinal Absorption , Appetite/drug effects , Receptors, Adrenergic, beta/therapeutic use
12.
Rev. Inst. Med. Trop. Säo Paulo ; 42(1): 23-6, Jan.-Feb. 2000. tab
Article in English | LILACS | ID: lil-254825

ABSTRACT

Our objective was to compare food intake and nutritional status of Pemphigus Foliaceus patients (PG) on long term glucocorticoid therapy to a Control Group (CG). Fourteen PG female inpatients receiving prednisone (0.33 + or - 0.22mg/kg) for at least 12 months and twelve CG subjects were submitted to nutritional evaluation, including anthropometry, urinary creatinine determination and serum biochemical measurements, besides 48-h-based food intake records. Groups were compared by Chi-square, Mann-Whitney and "t" tests. PG patients and CG were paired, respectively, in relation to age (24.7 + or - 14.1 vs. 22.0 + or - 12.0 years), body mass index (25.8 + or - 6.4 vs. 24.0 + or - 5.6kg/m2), daily protein intake (132.9 + or - 49.8 vs. 95.2 + or - 58.9g), and serum albumin (median; range) (3.8; 3.5-4.1 vs. 3.8; 3.6-5.0g/dl). However, PG patients had lower height-creatinine index (64.8 + or - 17.6 vs. 90.1 + or - 33.4 percent), and higher daily energy (3080 + or - 1099 vs. 2187 + or - 702kcal) and carbohydrate (376.8 + or - 135.8 vs. 242.0 + or - 80.7g) intakes. Despite high food, protein and energy consumption, PG patients on long term glucocorticoid therapy had lower body muscle mass than controls, while showing high body fat stores. These findings are possibly related to combined metabolic effects of long term corticotherapy and inflammatory disease plus corticosteroid-induced increased appetite


Subject(s)
Female , Humans , Eating , Glucocorticoids/therapeutic use , Nutritional Status , Pemphigus/drug therapy , Prednisone/therapeutic use , Anthropometry , Appetite/drug effects , Body Mass Index , Case-Control Studies , Creatinine/urine , Energy Intake , Pemphigus/blood , Pemphigus/urine , Serum Albumin/analysis , Time Factors
13.
Pediatr. día ; 15(5): 303-4, nov.-dic. 1999. ilus
Article in Spanish | LILACS | ID: lil-260135

ABSTRACT

La intoxicación por ciproheptadina, principal componente de los estimulantes del apetito, se ha transformado en un importante motivo de consulta en los servicios de urgencia a lo largo del país. Estos fármacos, utilizados muchas veces sin prescripción médica, dado su agradable sabor resultan atractivos para los preescolares quienes los ingieren en dosis que sobrepasan el nivel terapéutico, desencadenando cuadros muy variados, que van desde excitación psicomotora hasta la muerte


Subject(s)
Humans , Child , Adolescent , Appetite Stimulants/poisoning , Cyproheptadine/poisoning , Poisoning/therapy , Appetite/drug effects , Charcoal/therapeutic use , Cyproheptadine/administration & dosage , Cyproheptadine/pharmacokinetics , Gastric Lavage , Toxicological Symptoms
14.
Braz. j. med. biol. res ; 32(10): 1243-8, Oct. 1999. graf
Article in English | LILACS | ID: lil-252275

ABSTRACT

We have demonstrated that acute third ventricle injections of lead acetate (PbAc) exert a powerful antidipsogenic effect and induce a significant increase in renal sodium excretion. In the present study we confirm the antidipsogenic effect of lead and demonstrate that central administration of this metal, in minute amounts, significantly reduces salt intake both during dehydration and after central angiotensinergic stimulation. Adult male Wistar rats had the third ventricle cannulated seven days before the experiments. During this period they had free access to distilled water and hypertonic saline solution (1.5 percent). After a 24-h period of fluid deprivation, experimental animals received third ventricle injections of PbAc (0.3, N = 8 and 3.0 nmol/rat, N = 14) while controls received sodium acetate (NaAc; 3.0 nmol/rat, N = 10). Rats treated with PbAc at the highest dose showed a significant reduction both in water and hypertonic saline intake when compared to controls. When the effect of lead administration on angiotensin II-induced water and salt intake was studied, normohydrated animals received third ventricle injections of angiotensin II (9.6 nmol/rat) after pretreatment with 3.0 nmol/rat of PbAc (experimental group, N = 10) or NaAc (controls, N = 8). The group pretreated with PbAc presented a significant reduction in both water and salt intake compared to controls. Thus, this study confirms the antidipsogenic effect of central lead injections and demonstrates that the presence of lead in the brain exerts a significant inhibition of sodium appetite


Subject(s)
Rats , Animals , Male , Angiotensin II/pharmacology , Appetite/drug effects , Drinking/drug effects , Organometallic Compounds/administration & dosage , Sodium, Dietary/administration & dosage , Analysis of Variance , Body Fluids/drug effects , Injections, Intraventricular , Organometallic Compounds/pharmacology , Rats, Wistar
15.
Rev. méd. Minas Gerais ; 6(1): 20-5, jan.-mar. 1996. tab, graf
Article in Portuguese | LILACS | ID: lil-205986

ABSTRACT

O autor discute a obesidade em seus aspectos básicos, ou seja, o conceito, a fisiopatologia, os aspectos psicodinâmicos e as terapias propostas. Sugere uma abordagem do obeso no lugar da obesidade, procurando valorizar o impacto da relaçÝo médico-paciente suficientemente boa no tratamento de uma pessoa obesa.


Subject(s)
Humans , Obesity/physiopathology , Appetite/drug effects , Appetite Depressants/therapeutic use , Obesity/etiology , Obesity/psychology , Obesity/therapy
16.
JCPSP-Journal of the College of Physicians and Surgeons Pakistan. 1996; 6 (3): 167-72
in English | IMEMR | ID: emr-95973

ABSTRACT

Neurochemical research on a relationship between 5-hydroxytryptamine [5-HT; serotonin] and feeding shows that brain 5-HT metabolism is increased following the ingestion of a particularly carbohydrate rich diet. Increased metabolism may generate a neurochemical signal for the termination of the meal which is evidenced by pharmacological research on experimental animals and clinical reports. Receptor research shows that appetite suppressant effects of 5-HT are manifested by the stimulation of 5-HT-2B/5-HT-2C receptors located postsynaptically. Drugs with selectivity selectively towards 5-HT-1A receptors decreased the availability of 5-TH at these sites and elicited hyperphagia in experimental animals. It has been observed in clinical studies that availability of tryptophan [the precursor of 5-HT] to the brain is increased in anorexia associated with various diseases. However, psychological loss of appetite, as observed in anorexia nervosa, cannot be explained by the above hypothesis because evidence for enhanced 5-HT metabolism is lacing. On the other hand, underweight patients with clinical symptoms of anorexia nervosa exhibited low basal levels of 5-HIAA, a major metabolite of 5-HT, in the cerebrospinal fluid. Food restriction and self imposed dieting precipitate anorexia nervosa. Although brain 5-HT metabolism is increased following starvation, restricted feeding decreases it and the 5-HT synthesis rate, particularly in the hypothalamus. It is, therefore, possible that decreased presynaptic activity may provoke a compensatory up-regulation of postsynaptic receptors to precipitate anorexia nervosa. A greater sensitivity of these hypophagic serotonergic mechanisms in the female may put women at a greater risk to the disease


Subject(s)
Appetite/drug effects , Appetite Regulation/drug effects , Anorexia Nervosa/etiology , Rats , Eating , Hyperphagia
17.
Article in Spanish | LILACS | ID: lil-162412

ABSTRACT

El captopril ha mostrado la propiedad de disminuir el consumo de alcohol de ratas y también en un ensayo con un grupo de voluntarios sanos. Dada la importancia de esta proyección en la terapéutica de los alcohólicos, decidimos probar sus efectos en un grupo de ellos. La muestra fue un grupo de 14 alcohólicos diagnosticados según criterios DSM-III-R. El ensayo terapéutico fue randomizado, doble ciego y se usó placebo y captopril durante 12 semanas. Los resultados mostraron que ambos tratamientos redujeron significativamente: las cantidades de tragos estándar de alcohol ingeridas, el número de días de embriagueces semanales y de días de apetito alcohólico por semana y la intensidad del apetito. En este período, se embriagaron sólo el 43 por ciento de las veces que sintieron apetito, la gran mayoría de las veces con un apetito de intensidad leve o moderada, y a veces sin apetito. Concluimos que el efecto del captopril y del placebo son semejantes, que el apetito por alcohol no parece decisivo en la ingesta y que la motivación de los pacientes, el apoyo de su familia y del grupo profesional que los atendieron, explicaría los resultados favorables obtenidos


Subject(s)
Humans , Male , Adult , Appetite/drug effects , Captopril/pharmacology , Alcoholism/drug therapy , Placebos/administration & dosage , Placebos/pharmacology , Captopril/administration & dosage , Captopril/adverse effects , Captopril/therapeutic use , Case-Control Studies
18.
Arch. domin. pediatr ; 30(2): 30-2, mayo-ago. 1994. ilus
Article in Spanish | LILACS | ID: lil-170124

ABSTRACT

Analizamos el empleo de estimulantes del apetito en 300 madres de la ciudad de Santo Domingo, encontrando que el 54//los había utilizado en sus hijos. El mayor uso de estimulantes del apetito fue en varones (51.9//), en el primer hijo (54.3//), en el grupo de 2-4 años (33.3//), de madres con hogar completo y que no trabajaban, indicados generalmente por el pediatra (54.9//), en clínicas privadas (42.0//). La ciproheptadina es el más usado


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Adolescent , Appetite/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL